Data supports use of edoxaban in patients with atrial fibrillation undergoing cardioversion

 Results presented at ESC Congress 2016 in Rome, and published online in The Lancet support the use of edoxaban (Lixiana) in patients with atrial fibrillation undergoing cardioversion, it has been announced. The results, taken from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion, found that oral, once-daily edoxaban (Lixiana) met the study’s primary endpoints, demonstrating comparable efficacy and safety to well-managed enoxaparin/warfarin (mean time in therapeutic range on warfarin was 70.8%) for the prevention of stroke and other blood clot complications.  ENSURE-AF is a PROBE parallel group study designed to evaluate